The value of bone marrow scintigraphy using 99mtc monoclonal antigranulocyte antibodies in complement to bone scintigraphy in detecting bone metastases from primary breast cancer

Nuclear Medicine Communications

Volumn 24, Issue 1, 2003, Pages 29-36

  Prior, J O ^a   Barghouth, G ^a   Delaloye, J F ^a   Leyvraz, S ^a   Bischof delaloye, A ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Antigranulocyte monoclonal antibodies; Bone marrow scintigraphy; Bone metastases; Breast cancer; BW250 183; ROC analysis

Indexed keywords

BW 250 183; DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BONE; BONE MARROW; BONE TUMOR; BREAST TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; HUMAN; LABORATORY DIAGNOSIS; METASTASIS; MIDDLE AGED; QUALITY CONTROL; ROC CURVE; SCINTISCANNING; WHOLE BODY COUNTING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BONE AND BONES; BONE MARROW; BONE NEOPLASMS; BREAST NEOPLASMS; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MIDDLE AGED; QUALITY CONTROL; RADIOPHARMACEUTICALS; ROC CURVE; WHOLE-BODY COUNTING;

EID: 1842855740     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200301000-00012     Document Type: Article

References (30)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-156.
2. Reske SN. Recent advances in bone marrow scanning. Eur J Nucl Med 1991; 18: 203-221.
3. Smith BL. Approaches to breast cancer staging. N Engl J Med 2000; 342: 580-581.
4. Coleman RE, Rubens RD, Fogelman I. Reappraisal of the baseline bone scan in breast cancer. J Nucl Med 1988; 29: 1045-1049.
5. Fogelman I, McKillop JH. The bone scan in metastatic disease. In: Rubens RD, Fogelman I, eds. Bone metastases-diagnosis and treatment. Berlin, Heidelberg, New York: Springer, 1991: 31-62.
6. Altehoefer C, Ghanem N, Hogerle S, Moser E, Langer M. Comparative detectability of bone metastases and impact on therapy of magnetic resonance imaging and bone scintigraphy in patients with breast cancer. Eur J Radiol 2001; 40: 16-23.
7. Cook GJ, Fogelman I. The role of positron emission tomography in the management of bone metastases. Cancer 2000; 88: 2927-2933.
8. Steinsträsser A, Schorlemer HU, Schwarz A, Kuhlmann L, Bosselet K. A novel Tc-99m labeled antibody for in vivo targeting of granulocytes. J Nucl Med 1988; 29: P925.
9. Cremerius U, Buell U. The present role of bone marrow scintigraphy. Eur J Nucl Med 1999; 26: 191-193.
10. Reske SN, Karsten JH, Glöckner W. Bone marrow scintigraphy by means of Tc-99m labeled NCA-antibodies in breast carcinoma and malignant lymphoma. J Nucl Med 1989; 30: P820-821.
11. Reske SN, Karstens JH, Glöckner W, Steinsträsser A, Schwartz A, Ammon J, et al. Radioimmunoimaging for diagnosis of bone marrow involvement in breast cancer and malignant lymphoma. Lancet 1989; I: 299-301.
12. Reske S, Karstens J, Sohn M, Glöckner W, Buell U. Bone marrow immunoscintigraphy compared with conventional bone scintigraphy for the detection of bone metastases. Acta Oncologia 1993; 7: 753-761.
13. Duncker CM, Carrió I, Berná L, Estorch M, Alonso C, Ojeda B, et al. Radioimmune imaging of bone marrow in patients with suspected bone metastases from primary breast cancer. J Nucl Med 1990; 31: 1450-1455.
14. 99mTc-antigranulocyte bone marrow scintigraphy of breast and prostate skeletal metastases. Anticancer Res 1997; 17: 1615-1618.
15. Berna L, Torres G, Carrió I, Estorch M, Germa JR, Alonso C. Antigranulocyte antibody bone marrow scans in cancer patients with metastatic bone superscan appearance. Clin Nucl Med 1994; 19: 121-128.
16. Krause T, Reinhardt M, Nitzsche E, Moser E. Photopenic lesions in bone marrow scintigraphy using technetium-99m labeled antigranulocyte antibody without known tumour. Nuklearmedizin 1999; 38: 85-89.
17. Boubaker A, Bischof Delaloye A, Blanc CH, Dutoit M, Leyvraz PF, Delaloye B. Immunoscintigraphy with antigranulocyte monoclonal antibodies for the diagnosis of septic loosening of hip prostheses. Eur J Nucl Med 1995; 22: 139-147.
18. Lacic M, Bokulic T, Lukac J, Kovacic K, Baum RP, Kusic Z. Bone marrow immunoscintigraphy for the detection of skeletal metastases in patients with breast cancer. Nucl Med Commun 1999; 20: 135-143.
19. Sobin LH, Wittekind C. TNM classification of malignant tumours. 5th edition. New York: Wiley-Liss, 1997.
20. Greiner M, Pfeiffer D, Smith RD. Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. Prev Vet Med 2000; 45: 23-41.
21. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
22. Van Erkel AR, Pattynama PM. Receiver operating characteristic (ROC) analysis: basic principles and applications in radiology. Eur J Radiol 1998; 27: 88-94.
23. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39: 561-577.
24. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating curves: A non parametric approach. Biometrics 1988; 44: 837-845.
25. Kamby C, Vejborg I, Daugaard S, Goldhammer B, Dirksen H, Rossing N, et al. Clinical and radiologic characteristics of bone metastases in breast cancer. Cancer 1987; 60: 2524-2531.
26. Lee KH, Chung JK, Choi CW, Jeong JM, Lee DS, Bang YJ, et al. Technetium-99m-labeled anti-granulocyte antibody bone marrow scintigraphy. J Nucl Med 1995; 36: 1800-1805.
27. Roland J, Brans B, Vervaet A, Goor C, Servais J, de Meyere P, et al. Bone marrow content measured in radioimmune bone marrow scintigraphy: intra- and inter-observer variability. Nucl Med Commun 1999; 20: 419-426.
28. Braun S, Pantel K, Muller P, Jani W, Hepp F, Kentenich CR, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000; 342: 525-533.
29. Schirrmeister H, Guhlmann A, Kotzerke J, Santjohanser C, Kuhn T, Kreienberg T, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 1999; 17: 2381-2389.
30. m-MDP bone scintigraphy. Nucl Med Commun 2001; 22: 875-879.